BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, November 8, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» Post spinoff, Samsung Bioepis inks first ADC deal with Phrontline
To read the full story,
subscribe
or
sign in
.
Post spinoff, Samsung Bioepis inks first ADC deal with Phrontline
Oct. 21, 2025
By
Marian (YoonJee) Chu
No Comments
Samsung Bioepis Co. Ltd. announced Oct. 21 the signing of a license deal to codevelop, manufacture and commercialize two of Phrontline Biopharma Suzhou Co. Ltd.’s novel bispecific dual-payload antibody-drug conjugate (ADC) candidates.
BioWorld
BioWorld Asia
Deals and M&A
Cancer
Antibody-drug conjugate
Asia-Pacific
China
